# Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

> **NCT05027594** · PHASE1 · TERMINATED · sponsor: **Nerviano Medical Sciences** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** NMS-03597812
- **DRUG:** NMS-03597812 + dexamethasone

## Key facts

- **NCT ID:** NCT05027594
- **Lead sponsor:** Nerviano Medical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-09
- **Primary completion:** 2023-08-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The decision is not based on emerging safety or efficacy concerns but on strategic reasons related to the changing and competitive treatment options in Multiple Myeloma
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027594, "Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05027594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*